{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:17:46Z","timestamp":1791357466974,"version":"4.3.1"},"reference-count":44,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2012,6,26]],"date-time":"2012-06-26T00:00:00Z","timestamp":1340668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2012,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the efficacy, tolerability, and safety of multiple fixed dosages of esreboxetine for the treatment of fibromyalgia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients meeting the American College of Rheumatology criteria for fibromyalgia were randomized to receive esreboxetine at dosages of 4 mg\/day (n = 277), 8 mg\/day (n = 284), or 10 mg\/day (n = 283) or matching placebo (n = 278) for 14 weeks. The primary efficacy outcomes were the weekly mean pain score and the Fibromyalgia Impact Questionnaire (FIQ) total score at week 14. Secondary efficacy measures included scores for the Patient's Global Impression of Change (PGIC) scale, the Global Fatigue Index (GFI), and the 36\u2010item Short\u2010Form health survey (SF\u201036; physical function scale only) at week 14. The safety profile of esreboxetine was evaluated based on adverse events and other safety measures.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Patients receiving all dosages of esreboxetine demonstrated statistically significant improvements in the pain score (<jats:italic>P<\/jats:italic> \u2264 0.025), the FIQ score (<jats:italic>P<\/jats:italic> \u2264 0.023), and the PGIC score (<jats:italic>P<\/jats:italic> \u2264 0.007) compared with patients in the placebo group. Additionally, patients receiving esreboxetine at dosages of 4 mg\/day and 8 mg\/day showed statistically significant improvements in the GFI score compared with those receiving placebo (<jats:italic>P =<\/jats:italic> 0.001). No significant differences in SF\u201036 physical function scores were observed between patients receiving esreboxetine (any dosage) and those receiving placebo. Adverse events were mostly mild to moderate in severity; insomnia, constipation, dry mouth, nausea, dizziness, hot flush, headache, hyperhidrosis, and palpitations were reported most frequently.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Esreboxetine was generally well tolerated and was associated with significant improvements in pain, FIQ, PGIC, and fatigue scores compared with placebo. The lack of a dose\u2010response relationship in both the efficacy and safety analyses suggests that esreboxetine at a dosage of 4 mg\/day would offer clinical benefit with the least risk of drug exposure.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.34390","type":"journal-article","created":{"date-parts":[[2012,1,24]],"date-time":"2012-01-24T19:53:15Z","timestamp":1327434795000},"page":"2387-2397","source":"Crossref","is-referenced-by-count":37,"title":["Safety and efficacy of esreboxetine in patients with fibromyalgia: A fourteen\u2010week, randomized, double\u2010blind, placebo\u2010controlled, multicenter clinical trial"],"prefix":"10.1002","volume":"64","author":[{"given":"Lesley M.","family":"Arnold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,6,26]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380104"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-001-0021-2"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330203"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200002)13:1<42::AID-ART7>3.0.CO;2-R"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pec.2008.06.005"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar1971"},{"issue":"2","key":"e_1_2_7_8_2","first-page":"25","article-title":"Pharmacotherapy for patients with fibromyalgia","volume":"69","author":"Clauw DJ","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-002-0038-5"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S3396"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2010.01.002"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2005.06.031"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20485"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.08m00680"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100365"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.27559"},{"key":"e_1_2_7_17_2","first-page":"15","article-title":"Milnacipran for the management of fibromyalgia syndrome","volume":"3","author":"Ormseth MJ","year":"2010","journal-title":"J Pain Res"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1533-2500.2010.00403.x"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090884"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.psy.41.2.104"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.2000.06279.x"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-0082(02)00009-6"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1053\/eujp.1999.0148"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(94)00218-4"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.3109\/03009749409103725"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780391111"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(01)01089-0"},{"key":"e_1_2_7_28_2","doi-asserted-by":"crossref","first-page":"9040","DOI":"10.1523\/JNEUROSCI.20-24-09040.2000","article-title":"Potentiated opioid analgesia in norepinephrine transporter knock\u2010out mice","volume":"20","author":"Bohn LM","year":"2000","journal-title":"J Neurosci"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4637.2000.00042.x"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.psy.46.5.379"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2010.08.003"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(87)91074-8"},{"issue":"20","key":"e_1_2_7_33_2","first-page":"22","article-title":"The Mini\u2010International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM\u2010IV and ICD\u201010","volume":"59","author":"Sheehan DV","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_7_34_2","first-page":"135","volume-title":"Handbook of pain assessment","author":"Jensen MP","year":"1992"},{"key":"e_1_2_7_35_2","first-page":"728","article-title":"The Fibromyalgia Impact Questionnaire: development and validation","volume":"18","author":"Burckhardt CS","year":"1991","journal-title":"J Rheumatol"},{"key":"e_1_2_7_36_2","volume-title":"Clinical global impressions: ECDEU assessment manual for psychopharmacology","author":"Guy W","year":"1976"},{"key":"e_1_2_7_37_2","volume-title":"SF\u201036 Health Survey: manual and interpretation guide","author":"Ware JE","year":"1993"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006199-199303000-00006"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/75.4.800"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1081\/BIP-100104194"},{"key":"e_1_2_7_41_2","volume-title":"SAS for linear models","author":"Little RC","year":"2002"},{"key":"e_1_2_7_42_2","volume-title":"Categorical data analysis using the SAS system","author":"Stokes ME","year":"2000"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(01)00349-9"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.081090"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(99)70036-6"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.34390","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.34390","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T21:26:45Z","timestamp":1696973205000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.34390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,26]]},"references-count":44,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["10.1002\/art.34390"],"URL":"https:\/\/doi.org\/10.1002\/art.34390","archive":["Portico"],"relation":{},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,26]]}}}